Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.15 | — | — | 18.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.17 | 37.01 | 109.11 | 210.80 | 629.77 | 1112.37 | 610.32 | 455.05 | 730.33 | 230.41 | 213.01 | 3307.71 | — | — | — | — | — | — | — | — |
| — | -96.7% | -82.1% | -53.7% | -13.8% | +382.8% | +186.5% | -86.2% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.15 | 0.19 | 0.80 | 16.24 | 226.70 | 80.18 | 54.92 | 134.84 | 28.97 | 18.30 | — | 550.77 | 153.21 | 240.54 | 151.26 | 131.23 | 166.75 | 217.31 | 394.58 | — |
| — | -99.8% | -98.5% | -88.0% | +682.5% | +338.2% | — | -75.5% | -81.1% | -92.4% | — | +319.7% | -8.1% | +10.7% | -61.7% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 109.39 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 11.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6% | 25.1% | -7.7% | 81.6% | 88.6% | 66.2% | 45.1% | 92.7% | 25.9% | 14.3% | 27.0% | -1941.8% | — | — | — | — | — | — | — | — |
| — | -62.0% | -117.1% | -12.0% | +241.8% | +363.3% | +67.1% | +104.8% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -778.2% | -15950.9% | -9748.8% | -422.1% | -681.5% | -1259.6% | -1626.3% | -4093.7% | -650.3% | -1931.6% | -1582.2% | -9226.6% | — | — | — | — | — | — | — | — |
| — | -1166.3% | -499.4% | +89.7% | -4.8% | +34.8% | -2.8% | +55.6% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1721.0% | -16748.3% | -19643.4% | 1867.5% | -2892.7% | -2227.8% | -8408.8% | -4134.7% | -940.7% | -2029.8% | -1587.4% | -38229.5% | — | — | — | — | — | — | — | — |
| — | -651.8% | -133.6% | +145.2% | -207.5% | -9.8% | -429.7% | +89.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.6% | -22.7% | -30.6% | 59.2% | -189.2% | -45.5% | -121.0% | -116.3% | -10.0% | -136.2% | — | -384.0% | -45.9% | -41.9% | -13.5% | -13.4% | -16.7% | -23.0% | -23.0% | -83.2% |
| — | +50.0% | +74.7% | +151.0% | -1791.8% | +66.6% | — | +69.7% | +78.2% | -225.0% | — | -2771.0% | -174.7% | -82.3% | +41.3% | +83.9% | — | — | — | — | |
| ROA | -52.8% | -18.3% | -21.2% | 25.4% | -45.3% | -12.5% | -36.4% | -65.3% | -6.3% | -21.3% | -13.7% | -38.7% | -18.6% | -26.3% | -11.7% | -11.4% | -14.4% | -19.8% | -18.5% | -39.0% |
| — | -46.5% | +41.7% | +138.9% | -618.0% | +41.1% | -166.1% | -68.7% | +66.0% | +19.0% | -17.3% | -239.9% | -29.1% | -32.4% | +36.9% | +70.8% | — | — | — | — | |
| ROIC | -32.8% | -25.5% | -16.6% | -14.5% | -18.2% | -7.6% | -8.2% | -63.2% | -3.9% | -44.1% | -523.5% | -36.4% | -20.7% | -30.6% | — | — | — | — | — | — |
| — | -234.8% | -103.4% | +77.1% | -360.8% | +82.7% | +98.4% | -73.6% | +81.0% | -44.3% | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.02 | 0.00 | 0.05 | 1.48 | 2.00 | 0.98 | 0.25 | 0.43 | — | 7.04 | 1.26 | 1.01 | — | — | — | — | — | — |
| — | -99.1% | -98.8% | -99.7% | -80.0% | +244.2% | — | -86.0% | -80.5% | -57.2% | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.66 | 2.21 | 1.41 | 0.66 | 0.08 | 0.07 | 0.17 | 0.05 | 0.06 | 0.10 | 0.29 | 0.34 | 0.54 | 0.94 | 7.87 | 6.69 | 6.74 | 7.61 | 6.73 | 1.41 |
| — | +2920.0% | +719.1% | +1178.1% | +32.3% | -25.8% | -41.3% | -84.7% | -88.8% | -89.5% | -96.3% | -94.9% | -92.0% | -87.6% | +16.9% | +373.6% | — | — | — | — | |
| Quick Ratio | 0.65 | 2.14 | 1.37 | 0.65 | 0.07 | 0.06 | 0.16 | 0.05 | 0.05 | 0.09 | 0.28 | 0.32 | 0.46 | 0.84 | 7.87 | 6.69 | 6.74 | 7.61 | 6.73 | 1.41 |
| — | +3397.8% | +747.6% | +1236.7% | +32.3% | -32.7% | -41.4% | -84.8% | -88.4% | -89.2% | -96.5% | -95.2% | -93.2% | -88.9% | +16.9% | +373.6% | — | — | — | — | |
| Interest Coverage | -17.68 | -652.29 | -1877.29 | 1336.11 | -28.27 | -9.63 | -37.22 | -121.23 | -9.09 | -38.46 | -26.21 | -117.62 | -18.87 | -31.08 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONCO stock.
Onconetix, Inc.'s current P/E is -0.2x. The average P/E over the last 1 quarters is 18.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Onconetix, Inc.'s current operating margin is -778.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Onconetix, Inc.'s business trajectory between earnings reports.